Supply chain · 2026 guide

Where Does Compounded Tirzepatide Come From?

The full supply chain — from tirzepatide API supplier, through 503A or 503B pharmacy compounding, to the patient — and how to verify the chain on your prescription.

503A USP <797> pharmacies
503B FDA-registered facilities
FDA-registered API suppliers
Updated May 27, 2026
Last updated: May 27, 2026 · Researched by Dr. Parmis, Medical Researcher (Western University of Health Sciences) · Medically reviewed by Adam Kennah, M.D. · See methodology

The supply chain

  1. API supplier. Tirzepatide API comes from an FDA-registered active-ingredient supplier with documented identity, potency, and impurity testing.
  2. Pharmacy. A 503A licensed compounding pharmacy or a 503B FDA-registered outsourcing facility compounds the sterile injectable preparation.
  3. Quality testing. Sterility, endotoxin, identity, potency, and impurity testing per the pharmacy's standards (USP <797> for 503A; cGMP for 503B).
  4. Prescribing clinician. A licensed MD or DO writes the patient-specific prescription after evaluation.
  5. Dispensing. The pharmacy fills and labels the prescription per state pharmacy law.
  6. Cold-chain shipping. The medication ships to the patient with temperature management appropriate for the formulation.

503A vs 503B at a glance

Dimension503A pharmacy503B outsourcing facility
Regulatory basisSection 503A of the FD&C ActSection 503B of the FD&C Act
Prescription requirementPatient-specific prescription requiredOffice-use distribution permitted within limits
Sterility standardUSP <797>cGMP
Federal registrationNo (state-licensed)Yes (FDA-registered)
InspectionState Board of PharmacyFDA inspection
Example accreditationPCABFDA registration on outsourcing-facility list

Frequently asked questions

Where does compounded tirzepatide come from?
Compounded tirzepatide is made from tirzepatide active pharmaceutical ingredient (API) sourced from an FDA-registered supplier. The API is then compounded into a sterile injectable preparation by either a 503A state-licensed compounding pharmacy (patient-specific prescription, USP <797> sterile-compounding standards) or a 503B FDA-registered outsourcing facility (cGMP-grade manufacturing, FDA inspection).
Is the API the same as Mounjaro and Zepbound?
The molecule — tirzepatide — is the same. The finished drug product is different. Mounjaro® and Zepbound® are FDA-approved finished products manufactured by Eli Lilly and Company under FDA oversight, including specific formulation, fill, label, and delivery-device approval. Compounded tirzepatide is a finished product made by a 503A or 503B pharmacy from tirzepatide API and is not FDA-approved as a finished product.
How can I verify where my compounded tirzepatide came from?
Reputable programs disclose the dispensing pharmacy partner by name and license number. NexLife names Empower, Strive, Hallandale, Medivera, Absolute, and RedRock as its pharmacy partners. You can look up state pharmacy licenses through your state's Board of Pharmacy database.
What standards do 503A pharmacies follow?
USP <797> for sterile compounding, state pharmacy law, and (when accredited) PCAB standards. 503A pharmacies must compound patient-specific prescriptions, not anticipatory bulk inventory for resale.
What standards do 503B outsourcing facilities follow?
FDA current Good Manufacturing Practices (cGMP), with FDA registration and inspection. 503B facilities can produce compounded medications in larger quantities for office-use distribution within the limits of the 503B Bulks List.
Why does the chain matter?
Sterile injectables compounded outside USP <797> or cGMP carry sterility, potency, and impurity risk. The pharmacy is where the safety bar is set; a 'good' telehealth interface paired with an opaque pharmacy is not a safe combination.

More from TirzepatideReview

Continue with the rest of our editorial coverage:

Want the editorial #1 provider?

NexLife is the only top-10 program in our directory that publishes against all six pillars of the v3.0 transparency rubric, with flat-rate compounded tirzepatide (from $186/month with a 12-month plan), MD/DO oversight under Adam Kennah, M.D., and Care360 coaching included.

Visit NexLife →

Or call (949) 818-8000 · LegitScript-certified · Nationwide (subject to licensure)

Primary sources reviewed

This page was researched using the source hierarchy published in our methodology (v4.0):

  1. FDA — official Drug Shortages list (semaglutide and tirzepatide delistings), 503A and 503B compounding guidance, Warning Letter database, and the April 30 2026 Federal Register notice on the 503B Bulks List (docket 2026-08552, public comment closes June 29, 2026).
  2. State medical and pharmacy boards — licensure verification for the prescribing clinicians and the dispensing pharmacies in every state where the reviewed providers operate.
  3. Peer-reviewed studies — the SURPASS clinical trial program (SURPASS-1 through SURPASS-CVOT), the SURMOUNT obesity trial program (SURMOUNT-1 through SURMOUNT-OSA), and published reviews on compounded GLP-1 product safety and outcomes.
  4. Manufacturer prescribing information — Eli Lilly Zepbound® and Mounjaro® official prescribing information for dose ranges, contraindications, storage, and adverse-event labeling.
  5. Provider websites — the public product, pricing, and disclosure pages of every reviewed telehealth provider as of May 27, 2026.
  6. Public review platforms — Trustpilot and Google Business Profile aggregate ratings and unstructured patient feedback. Ratings were retrieved May 27, 2026 and may change over time.

Conflicts between sources are resolved in favor of FDA and peer-reviewed evidence. Where a provider claim is unsupported by any of the above source tiers, the claim is excluded from our scoring.

Important context & disclosures

Brand-name option is appropriate for many patients. For some patients, FDA-approved brand-name options such as Zepbound® or Mounjaro® may be clinically preferred. Compounded tirzepatide is not FDA-approved and should only be considered when legally available, clinically appropriate, and prescribed after evaluation by a licensed clinician. Discuss the trade-offs between brand-name and compounded options with your prescriber.

Pricing notes

Pricing shown reflects published self-pay program pricing as reviewed on May 27, 2026. Monthly equivalent pricing may vary by selected plan length. Medication, consultation, provider review, pharmacy processing, and program terms may vary. Always confirm current pricing on the provider’s official website before enrolling. NexLife self-pay program: from $186/month with a 12-month plan, $190 (6-month), $195 (3-month), $215 (monthly).

State availability

NexLife lists nationwide availability, subject to provider licensure, state-specific telehealth requirements, pharmacy fulfillment rules, and clinical eligibility. Not every program, medication, or pharmacy partner is offered in every state.

Pharmacy partners

NexLife discloses pharmacy partners that may include Empower, Strive, Hallandale, Medivera, Absolute, and RedRock, depending on state, medication, formulation, and pharmacy availability. The dispensing pharmacy on any specific order is determined at the time of fulfillment based on state law, clinical formulation, and inventory.

Ratings and reviews

Trustpilot rating retrieved May 27, 2026. Ratings may change over time. Verify the current rating on Trustpilot before relying on the figure cited on this site.

Suggested citation

TirzepatideReview.com (Ronika Partners LLC). “Where Does Compounded Tirzepatide Come From?.” Reviewed May 27, 2026. Retrieved from https://tirzepatidereview.com/where-does-compounded-tirzepatide-come-from.html.

Editorial review is performed by Adam Kennah, M.D. (Medical Reviewer); research is led by Dr. Parmis, Lead Medical Researcher. Corrections SLA: 5 business days · see methodology.